CSS
VKTX icon

Cubist Systematic Strategies’s Viking Therapeutics VKTX Stock Holding History

Cubist Systematic Strategies’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,900
Closed -$533K – 3959
2023
Q2 		$533K Buy
+32,900
New +$689K ﹤0.01% 2350

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cubist Systematic Strategies's VKTX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Viking Therapeutics (VKTX) stake by 89% in Q3 2025, selling an estimated $15.9M and leaving 64,355 shares worth $1.69M. The position accounts for 0.01% of the portfolio, ranked #1663.

Cubist Systematic Strategies first reported a position in VKTX in Q2 2018 and has held it in 18 quarters since. The position peaked at $15.8M in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Cubist Systematic Strategies held 64,355 shares of Viking Therapeutics worth $1.69M as of Q3 2025.
  • Cubist Systematic Strategies sold 532,295 Viking Therapeutics shares in Q3 2025, an estimated $15.9M.
  • Viking Therapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1663 holding.
  • Cubist Systematic Strategies first reported a position in Viking Therapeutics in Q2 2018 and has held it in 18 quarters since.
  • Cubist Systematic Strategies's Viking Therapeutics position peaked at $15.8M in Q2 2025.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.